4 Firms Guide Swedish Pharma's $1.7B Offer For US Rival
Swedish pharmaceutical company Sobi said on Wednesday that it has agreed to acquire its U.S. rival CTI BioPharma Corp. for $1.7 billion in a deal guided by firms including Latham &...To view the full article, register now.
Already a subscriber? Click here to view full article